ES2051754T3 - Uso de derivados cetonicos en el tratamiento de la depresion. - Google Patents

Uso de derivados cetonicos en el tratamiento de la depresion.

Info

Publication number
ES2051754T3
ES2051754T3 ES87311082T ES87311082T ES2051754T3 ES 2051754 T3 ES2051754 T3 ES 2051754T3 ES 87311082 T ES87311082 T ES 87311082T ES 87311082 T ES87311082 T ES 87311082T ES 2051754 T3 ES2051754 T3 ES 2051754T3
Authority
ES
Spain
Prior art keywords
depression
treatment
methyl
ketonic derivatives
ketonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87311082T
Other languages
English (en)
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2051754T3 publication Critical patent/ES2051754T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL EMPLEO DE 1,2,3,9-TETRAHIDRO-9-METIL -3-[(2 METIL-1H-IMIDAZOL-1-IL)METIL]-4H-CARBAZOL-4-ONA Y SUS SALES Y SOLVATOS FISIOLOGICAMENTE ACEPTABLES, EN EL TRATAMIENTO DE LA DEPRESION.
ES87311082T 1986-12-17 1987-12-16 Uso de derivados cetonicos en el tratamiento de la depresion. Expired - Lifetime ES2051754T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630071A GB8630071D0 (en) 1986-12-17 1986-12-17 Medicaments

Publications (1)

Publication Number Publication Date
ES2051754T3 true ES2051754T3 (es) 1994-07-01

Family

ID=10609112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87311082T Expired - Lifetime ES2051754T3 (es) 1986-12-17 1987-12-16 Uso de derivados cetonicos en el tratamiento de la depresion.

Country Status (18)

Country Link
US (1) US4835173A (es)
EP (1) EP0276559B1 (es)
JP (1) JP2732844B2 (es)
KR (1) KR880007073A (es)
AT (1) ATE79031T1 (es)
AU (1) AU608794B2 (es)
CY (1) CY1693A (es)
DE (1) DE3780940T2 (es)
DK (1) DK662787A (es)
ES (1) ES2051754T3 (es)
GB (1) GB8630071D0 (es)
GR (1) GR3005682T3 (es)
HK (1) HK36593A (es)
IE (1) IE60135B1 (es)
IL (1) IL84844A0 (es)
NZ (1) NZ222949A (es)
PH (1) PH25503A (es)
ZA (1) ZA879458B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246941A (en) * 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
JPS63277622A (ja) * 1986-12-17 1988-11-15 グラクソ、グループ、リミテッド 医薬
GB8820653D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP0591434A4 (en) * 1991-06-26 1994-09-14 Sepracor Inc Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
EP1181015A2 (en) 1999-03-01 2002-02-27 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
KR20070054749A (ko) * 2001-01-11 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 순수한 온단세트론 하이드로클로라이드 이수화물의 개선된제조 방법
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
DE60314400T2 (de) * 2002-04-29 2008-02-07 Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag Verfahren zur herstellung von 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-on
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
AU2019290925B9 (en) * 2018-06-21 2025-08-21 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (NAD+) precursor and at least one ketone or ketone precursor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (es) * 1981-06-09 1987-02-28 Ici Plc
LU85743A1 (fr) * 1984-01-25 1986-08-04 Glaxo Group Ltd Composes heterocycliques
GB8401888D0 (en) * 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
DE385517T1 (de) * 1985-03-14 1991-07-25 Beecham Group p.l.c., Brentford, Middlesex Arzneimittel zur behandlung von erbrechen.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.

Also Published As

Publication number Publication date
EP0276559A3 (en) 1989-10-18
IE60135B1 (en) 1994-06-01
GB8630071D0 (en) 1987-01-28
AU608794B2 (en) 1991-04-18
EP0276559A2 (en) 1988-08-03
GR3005682T3 (es) 1993-06-07
ATE79031T1 (de) 1992-08-15
PH25503A (en) 1991-07-24
KR880007073A (ko) 1988-08-26
HK36593A (en) 1993-04-23
JP2732844B2 (ja) 1998-03-30
NZ222949A (en) 1997-06-24
IE873415L (en) 1988-06-17
DK662787D0 (da) 1987-12-16
JPS63165314A (ja) 1988-07-08
DE3780940T2 (de) 1992-12-24
US4835173A (en) 1989-05-30
ZA879458B (en) 1988-11-30
IL84844A0 (en) 1988-06-30
AU8261787A (en) 1988-06-23
CY1693A (en) 1994-01-14
EP0276559B1 (en) 1992-08-05
DK662787A (da) 1988-06-18
DE3780940D1 (de) 1992-09-10

Similar Documents

Publication Publication Date Title
ES2051754T3 (es) Uso de derivados cetonicos en el tratamiento de la depresion.
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ES2162268T3 (es) Composiciones cosmeticas a base de pirazolin-4,5-dionas, nuevas pirazolin-4,5-dionas, procedimientos de preparacion y utilizaciones.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
YU26691A (sh) BORNO KISELINSKI ADUKTI RENIJUM DIOKSIM I TEHNICIJUM-99 m DIOKSIM KOMPLEKSA I PRIBOR ZA MARKIRANJE SA TEHNICIJUMOM 99 m I/ILI RADIONUKLEIDOM RENIJUMA
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
SE8501709D0 (sv) Improvements in or relating to intrleukin therapy
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
SE8804629D0 (sv) New therapeutically active compounds
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2052585T3 (es) Uso de derivados cetonicos en el tratamiento de desordenes cognitivos.
DK76582A (da) Antimycotiske midler
ES2118955T3 (es) Derivados de dolastatina.
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
FR2609391B1 (fr) Preparations pharmaceutiques sous forme de suppositoires bioadhesifs
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
NO913686L (no) Fremgangsmaate for fremstilling av 9-substituerte guaninderivater og mellomprodukter for anvendelse i fremgangsmaaten.
IT8022185A0 (it) Strumento per la cura dei piedi di notevole versatilita' di uso.
IT1213323B (it) Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
IT1251838B (it) Uso della nimesulide nel trattamento della cataratta

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276559

Country of ref document: ES